New Formulation of Jadenu Approved

The Food and Drug Administration (FDA) has approved Jadenu Sprinkle (deferasirox) granules for the treatment of chronic iron overload due to blood transfusions in patients aged ≥2 years and for the treatment of chronic iron overload in non-transfusion-dependent thalassemia (NTDT) syndromes in patients aged ≥10 years.

Like the tablet formulation, the new Sprinkle granules should also be taken on an empty stomach or with a light meal. The full dose of the Sprinkle granules can be sprinkled on soft food (eg, yogurt, applesauce) right before use and given orally. Both the tablets and granules should not be taken with aluminum-containing antacid products. The drug labeling contains additional information for patients who are on current chelation therapy with Exjade (deferasirox) tablets for oral suspension and converting to Jadenu. 

Jadenu is currently available as 90mg, 180mg, and 360mg strength tablets in 30-count bottles. Jadenu Sprinkle will be available as 90mg, 180mg, and 360mg strength granules in cartons of 30 sachets.

For more information call (888) 669-6682 or visit Jadenu.com.